Vincamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Vincamine
Accession Number
DB13374
Type
Small Molecule
Groups
Experimental
Description

Vincamine is a monoterpenoid indole alkaloid obtained from the leaves of Vinca minor with a vasodilatory property. Studies indicate that vincamine increases the regional cerebral blood flow.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
996XVD0JHT
CAS number
1617-90-9
Weight
Average: 354.45
Monoisotopic: 354.194342705
Chemical Formula
C21H26N2O3
InChI Key
RXPRRQLKFXBCSJ-GIVPXCGWSA-N
InChI
InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
IUPAC Name
methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
SMILES
[H][C@]12N3CCC[C@@]1(CC)C[C@@](O)(N1C4=CC=CC=C4C(CC3)=C21)C(=O)OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Vincamine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Vincamine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Vincamine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Vincamine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Vincamine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Vincamine.Approved, Withdrawn
AmbrisentanVincamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineVincamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Vincamine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Vincamine.Approved, Illicit, Investigational
AtenololAtenolol may increase the hypotensive activities of Vincamine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Vincamine.Approved
BarnidipineVincamine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Vincamine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Vincamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Vincamine.Withdrawn
BepridilBepridil may increase the hypotensive activities of Vincamine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Vincamine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Vincamine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Vincamine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Vincamine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Vincamine.Approved
BosentanBosentan may increase the hypotensive activities of Vincamine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Vincamine.Investigational
BretyliumBretylium may increase the hypotensive activities of Vincamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Vincamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Vincamine.Experimental
BupranololBupranolol may increase the hypotensive activities of Vincamine.Approved
CadralazineCadralazine may increase the hypotensive activities of Vincamine.Experimental
CafedrineCafedrine may increase the hypotensive activities of Vincamine.Investigational
CandesartanVincamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Vincamine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Vincamine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Vincamine.Approved
CarbomycinThe serum concentration of Vincamine can be increased when it is combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Vincamine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Vincamine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Vincamine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Vincamine.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Vincamine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Vincamine.Approved
CicletanineCicletanine may increase the hypotensive activities of Vincamine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Vincamine.Approved
ClarithromycinThe serum concentration of Vincamine can be increased when it is combined with Clarithromycin.Approved
ClonidineClonidine may increase the hypotensive activities of Vincamine.Approved
CloranololVincamine may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Vincamine.Approved
CyclopenthiazideVincamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Vincamine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Vincamine.Approved, Investigational
DelaprilDelapril may increase the hypotensive activities of Vincamine.Experimental
DeserpidineVincamine may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Vincamine.Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Vincamine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Vincamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Vincamine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Vincamine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Vincamine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Vincamine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Vincamine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Vincamine.Approved
EndralazineEndralazine may increase the hypotensive activities of Vincamine.Experimental
EpanololVincamine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Vincamine.Approved
EprosartanEprosartan may increase the hypotensive activities of Vincamine.Approved
ErythromycinThe serum concentration of Vincamine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Vincamine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Vincamine.Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Vincamine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Vincamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Vincamine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Vincamine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Vincamine.Approved
GuanazodineVincamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Vincamine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Vincamine.Approved, Investigational
GuanoclorVincamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzVincamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanVincamine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Vincamine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Vincamine.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Vincamine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Vincamine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Vincamine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Vincamine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Vincamine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Vincamine.Investigational
IndapamideIndapamide may increase the hypotensive activities of Vincamine.Approved
IndenololIndenolol may increase the hypotensive activities of Vincamine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Vincamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Vincamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Vincamine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Vincamine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Vincamine.Approved
IsradipineIsradipine may increase the hypotensive activities of Vincamine.Approved, Investigational
JosamycinThe serum concentration of Vincamine can be increased when it is combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Vincamine.Investigational
KitasamycinThe serum concentration of Vincamine can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Vincamine.Approved
LacidipineLacidipine may increase the hypotensive activities of Vincamine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Vincamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Vincamine.Approved, Investigational
LinsidomineVincamine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Vincamine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Vincamine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Vincamine.Approved
MacitentanVincamine may increase the hypotensive activities of Macitentan.Approved
ManidipineManidipine may increase the hypotensive activities of Vincamine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Vincamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Vincamine.Approved, Investigational
MethoserpidineVincamine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Vincamine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Vincamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Vincamine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Vincamine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Vincamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Vincamine.Approved, Investigational
MetyrosineVincamine may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Vincamine.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Vincamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Vincamine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Vincamine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Vincamine is combined with Mitomycin.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Vincamine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Vincamine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Vincamine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Vincamine.Approved, Investigational
MuzolimineVincamine may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the hypotensive activities of Vincamine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Vincamine.Investigational
NebivololNebivolol may increase the hypotensive activities of Vincamine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Vincamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Vincamine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Vincamine.Approved, Investigational
NiguldipineNiguldipine may increase the hypotensive activities of Vincamine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Vincamine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Vincamine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Vincamine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Vincamine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Vincamine.Approved, Investigational
ObinutuzumabVincamine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Vincamine.Withdrawn
OleandomycinThe serum concentration of Vincamine can be increased when it is combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Vincamine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Vincamine.Investigational
OxprenololOxprenolol may increase the hypotensive activities of Vincamine.Approved
PargylinePargyline may increase the hypotensive activities of Vincamine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Vincamine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Vincamine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Vincamine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Vincamine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Vincamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Vincamine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Vincamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Vincamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Vincamine.Approved
PinacidilPinacidil may increase the hypotensive activities of Vincamine.Approved
PindololPindolol may increase the hypotensive activities of Vincamine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Vincamine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Vincamine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Vincamine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Vincamine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vincamine.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Vincamine.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Vincamine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Vincamine.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Vincamine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Vincamine.Approved
RamiprilRamipril may increase the hypotensive activities of Vincamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Vincamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Vincamine.Approved
RescinnamineVincamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Vincamine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Vincamine.Approved, Investigational
RiociguatVincamine may increase the hypotensive activities of Riociguat.Approved
RituximabVincamine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Vincamine.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Vincamine.Experimental
SelegilineSelegiline may increase the hypotensive activities of Vincamine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Vincamine.Approved
SildenafilSildenafil may increase the antihypertensive activities of Vincamine.Approved, Investigational
SitaxentanVincamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe serum concentration of Vincamine can be increased when it is combined with Solithromycin.Investigational
SpiramycinThe serum concentration of Vincamine can be increased when it is combined with Spiramycin.Approved
SpiraprilSpirapril may increase the hypotensive activities of Vincamine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Vincamine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Vincamine.Investigational
TelithromycinThe serum concentration of Vincamine can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Vincamine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Vincamine.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Vincamine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Vincamine.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Vincamine.Investigational
TiboloneTibolone may increase the hypotensive activities of Vincamine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Vincamine.Withdrawn
TimololTimolol may increase the hypotensive activities of Vincamine.Approved
TolazolineTolazoline may increase the hypotensive activities of Vincamine.Approved, Vet Approved
TolonidineVincamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Vincamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Vincamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Vincamine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Vincamine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Vincamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Vincamine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Vincamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Vincamine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Vincamine.Approved, Investigational
TylosinThe serum concentration of Vincamine can be increased when it is combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Vincamine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Vincamine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Vincamine.Investigational
ValsartanValsartan may increase the hypotensive activities of Vincamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Vincamine.Approved
VinpocetineVinpocetine may increase the hypotensive activities of Vincamine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vincamine.Approved, Investigational
XipamideVincamine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Vincamine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Vincamine.Approved, Investigational, Vet Approved
ZofenoprilZofenopril may increase the hypotensive activities of Vincamine.Experimental
Food Interactions
Not Available

References

General References
  1. Hagstadius S, Gustafson L, Risberg J: The effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi-infarct dementia. Psychopharmacology (Berl). 1984;83(4):321-6. [PubMed:6436861]
External Links
KEGG Compound
C09251
PubChem Compound
15376
PubChem Substance
347829295
ChemSpider
14635
ChEBI
9985
ChEMBL
CHEMBL1165342
Wikipedia
Vincamine
ATC Codes
C04AX07 — Vincamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.216 mg/mLALOGPS
logP2.62ALOGPS
logP3.39ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)10.52ChemAxon
pKa (Strongest Basic)6.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.7 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity99.57 m3·mol-1ChemAxon
Polarizability39.39 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0006-0092000000-7408330df526558920e8
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0009000000-8f742bc50bb6ffaadcf1
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0009000000-e477ed23d437d91bcacc
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4j-0019000000-856c214b29871969e3ec
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001c-0593000000-3e0598831094cc184110

Taxonomy

Description
This compound belongs to the class of organic compounds known as eburnan-type alkaloids. These are alkaloids with a structure based on the eburnan skeleton, that arises from rearrangement of the aspidospermidine ring system, involving migration of C-21 from C-7 to C-2, fission of the 2,16-bond, and attachment of C-16 to N-1.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Eburnan-type alkaloids
Sub Class
Not Available
Direct Parent
Eburnan-type alkaloids
Alternative Parents
Indolonaphthyridine alkaloids / Beta carbolines / 3-alkylindoles / Alpha amino acids and derivatives / Naphthyridines / Aralkylamines / Piperidines / Benzenoids / Pyrroles / Methyl esters
show 9 more
Substituents
Eburna alkaloid / Indolo[3,2-1de][1,5]naphthyridine / Beta-carboline / Pyridoindole / Diazanaphthalene / Alpha-amino acid or derivatives / Naphthyridine / 3-alkylindole / Indole / Indole or derivatives
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound, methyl ester, hemiaminal, alkaloid ester, vinca alkaloid (CHEBI:9985) / Indole alkaloids (C09251)

Drug created on June 23, 2017 14:40 / Updated on May 02, 2018 00:32